Childhood psychiatric disorders

SAY Premieres LIVE Stream Virtual Benefit 'Under One Moon' During National Stuttering Awareness Week May 15, 2020 6:00 PM EST

Retrieved on: 
Friday, May 8, 2020
Speech impediments, Psychiatry, Dyslexia, Psychiatric diagnosis, Stuttering, Childhood psychiatric disorders, Cornman, National Stuttering Awareness Week, Human behavior

NEW YORK, May 7, 2020 /PRNewswire/ -- SAY: The Stuttering Association for the Young ( www.say.org ) is thrilled to announce its first-ever LIVE Virtual Benefit Under One Moon on Friday, May 15, 2020 at 6:00 PM EST.

Key Points: 
  • NEW YORK, May 7, 2020 /PRNewswire/ -- SAY: The Stuttering Association for the Young ( www.say.org ) is thrilled to announce its first-ever LIVE Virtual Benefit Under One Moon on Friday, May 15, 2020 at 6:00 PM EST.
  • "The incredible public response we've received to Morning Song really helped spark the idea for this exciting live stream benefit," Cornman notes.
  • It is fitting that Under One Moon will premiere during National Stuttering Awareness Week, running from May 11-17, 2020.
  • To learn more about SAY's live stream virtual benefit, Under One Moon, visit www.SAYBenefit.org .

American BriVision Conducts Site Monitoring Visit for Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)

Retrieved on: 
Monday, April 6, 2020
Psychiatry, Methylphenidate, Childhood psychiatric disorders, Abnormal psychology, Amphetamine, Educational psychology, Attention deficit hyperactivity disorder, Adult attention deficit hyperactivity disorder, Attention deficit hyperactivity disorder controversies

This trial is an open label, single-center and dose escalation study designed for the enrollment of six adult ADHD patients.

Key Points: 
  • This trial is an open label, single-center and dose escalation study designed for the enrollment of six adult ADHD patients.
  • As of the site monitoring visit, four qualified adult ADHD patients had been enrolled and treated with PDC-1421 Capsules.
  • Among them, two will complete their treatment of PDC-1421 according to the study protocol on April 8 and April 11, 2020 respectively.
  • The overall site monitoring visit went well with several minor errors cited and corrected subsequently.

2020 Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 11, 2020
Health, General Health, Psychiatry, Methylphenidate, Childhood psychiatric disorders, Neuroscience, Educational psychology, Psychiatric diagnosis, Amphetamine, Attention deficit hyperactivity disorder, Attention deficit, Adhansia XR, Hyperkinetic disorder

The "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2020, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.
  • The Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Meritech Selects DevelopmentalFX as Philanthropic Partner to Support Children with Neurodevelopmental Disorders

Retrieved on: 
Monday, March 9, 2020
Psychiatry, Developmental neuroscience, Psychiatric diagnosis, Neuroscience, Organ systems, Developmental disabilities, Childhood psychiatric disorders, Neurodevelopmental disorders, Developmental disorder, Mental disorder

"DevelopmentalFX stood out to us among the charitable organizations we considered due to their truly unique approach in empowering children, families, schools, and communities that are affected by neurodevelopmental disorders so that all children may be uplifted to achieve their fullest potential."

Key Points: 
  • "DevelopmentalFX stood out to us among the charitable organizations we considered due to their truly unique approach in empowering children, families, schools, and communities that are affected by neurodevelopmental disorders so that all children may be uplifted to achieve their fullest potential."
  • DevelopmentalFX is a nonprofit organization based in Denver, Colorado that works with children that have a range of learning and developmental disabilities.
  • "We are thrilled to partner with Meritech in supporting their organizational mission and values while also galvanizing community support to transform the lives of children and families affected by neurodevelopmental disorders," says Tracy Stackhouse, DevelopmentalFX Co-Founder, and Executive Director.
  • DevelopmentalFX is a Denver-based nonprofit organization whose mission is to transform the lives of children and families affected by neurodevelopmental disorders so that they can live to their fullest potential.

National Stuttering Association's Baton Rouge Chapter Hosts 4th Annual Open House

Retrieved on: 
Thursday, February 27, 2020
Dyslexia, Psychiatric diagnosis, Psychiatry, National Stuttering Association, Childhood psychiatric disorders, Baton Rouge, Louisiana, Stuttering, Medical diagnosis

BATON ROUGE, La., Feb. 27, 2020 /PRNewswire/ -- The National Stuttering Association 's Baton Rouge chapter is holding an open house Monday, March 2nd, 2020 from 7:00PM-9:00PM.

Key Points: 
  • BATON ROUGE, La., Feb. 27, 2020 /PRNewswire/ -- The National Stuttering Association 's Baton Rouge chapter is holding an open house Monday, March 2nd, 2020 from 7:00PM-9:00PM.
  • Born and raised in Baton Rouge, and a grad student of Southern University,this year's open house host, Melvin B. Givens is also a person who stutters.
  • "We want everyone who stutters, or has an interest in, or been affected by stuttering to feel welcome to this event.
  • The National Stuttering Association, originally named the National Stuttering Project, was founded in California by Bob Goldman and Michael Sugarman in 1977.

Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health

Retrieved on: 
Monday, February 24, 2020
Technology, Other Technology, Clinical trials, Audio, Video, Biotechnology, Other Health, Alternative medicine, Health, Pharmaceutical, Psychiatry, Attention deficit hyperactivity disorder, Psychology, Human behavior, Childhood psychiatric disorders, Psychiatric diagnosis, Educational psychology, Amphetamine, Impulsivity, Attention deficit hyperactivity disorder controversies, Hyperkinetic disorder

Akili Interactive today announced that results from the STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD) were published in The Lancet Digital Health journal.

Key Points: 
  • Akili Interactive today announced that results from the STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD) were published in The Lancet Digital Health journal.
  • ADHD is a disorder marked by a persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
  • The STARS-ADHD pivotal study of AKL-T01 was a randomized, double-blind, active-controlled study conducted across 20 sites.
  • Akili is pioneering the development of digital treatments and care solutions to help people affected by cognitive impairments.

All About Ability Hosts "Able Awards" Ceremony For Commitment To Independence For Adults With Disabilities

Retrieved on: 
Thursday, February 20, 2020
Disability, Psychiatric diagnosis, Special education, Educational psychology, Psychiatry, Childhood psychiatric disorders, Learning, Learning disabilities, Articles

Local VIPs, including Mayors and State representatives serving Sonoma and Napa Counties, for their ongoing commitment to independence for adults with disabilities living in our communities; and

Key Points: 
  • Local VIPs, including Mayors and State representatives serving Sonoma and Napa Counties, for their ongoing commitment to independence for adults with disabilities living in our communities; and
    Independent Living Skills staff and program participants in reaching awesome milestones toward adult independence.
  • All About Ability is a support program for adults with intellectual, processing, learning and developmental struggles, and their families.
  • All About Ability supports individuals with everyday living tasks helping them develop a "circle of support" to live as independently as possible.
  • The company truly believes in building on personal strength in the least restrictive environment possible while learning new life skills in the process.

Global Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Overview 2020: Emerging Therapies, Unmet Needs, Product Profiles, Key Players

Retrieved on: 
Wednesday, February 19, 2020
Psychiatry, Psychology, Medicine, Psychiatric diagnosis, Childhood psychiatric disorders, Amphetamine, Methylphenidate, Attention deficit hyperactivity disorder, Hyperkinetic disorder, ADHD rating scale

Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.

Key Points: 
  • Attention-Deficit/Hyperactivity Disorder (ADHD) Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Attention-deficit/hyperactivity disorder (ADHD) market.
  • A detailed picture of the Attention-deficit/hyperactivity disorder (ADHD) pipeline landscape is provided, which includes the disease overview and Attention-deficit/hyperactivity disorder (ADHD) treatment guidelines.
  • The assessment part of the report embraces in-depth Attention-deficit/hyperactivity disorder (ADHD) commercial assessment and clinical assessment of the Attention-deficit/hyperactivity disorder (ADHD) pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Attention-deficit/hyperactivity disorder (ADHD) emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Attention-deficit/hyperactivity disorder (ADHD)?

BrainsWay Announces Data from Feasibility Study of Deep Transcranial Magnetic Stimulation System in the treatment of Adults with ADHD

Retrieved on: 
Monday, February 10, 2020
Neuroscience, Psychiatry, Branches of biology, Childhood psychiatric disorders, Neuropsychology, Neurotechnology, Amphetamine, Methylphenidate, Brainsway, Attention deficit hyperactivity disorder, Attention deficit hyperactivity disorder controversies, Attention deficit hyperactivity disorder management

Additional study of this non-invasive treatment approach in this population is warranted.

Key Points: 
  • Additional study of this non-invasive treatment approach in this population is warranted.
  • The study enrolled 75 adults, ages 18-60 years, with ADHD who had not previously received TMS.
  • This study adds to the growing body of clinical evidence demonstrating the potential clinical benefits of dTMS in the treatment of ADHD.
  • BrainsWay is engaged in the research, development and sales and marketing of a medical system for non-invasive treatment of common brain disorders.

Top 10 Advances in Psychiatric Research for 2019 from the Brain & Behavior Research Foundation

Retrieved on: 
Thursday, January 23, 2020
Psychiatry, Psychology, Psychiatric diagnosis, Psychopathology, Abnormal psychology, Childhood psychiatric disorders, Mental disorder, Psychiatric assessment, Attention deficit hyperactivity disorder, Psychosis, Spectrum disorder, Outline of abnormal psychology

New York, Jan. 23, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation, the largest private funder of mental health research grants, has announced the 2019 Leading Research Achievements by BBRF Grantees, Prizewinners & Scientific Council Members.

Key Points: 
  • New York, Jan. 23, 2020 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation, the largest private funder of mental health research grants, has announced the 2019 Leading Research Achievements by BBRF Grantees, Prizewinners & Scientific Council Members.
  • Research progress has been reported in schizophrenia, psychosis, ADHD, anxiety, bipolar disorder, eating disorders, autism spectrum disorder, PTSD, depression and addiction.
  • In supporting psychiatric research, our goal is to better understand the causes and develop new ways to treat brain and behavior disorders.
  • Science, November 2019
    The Brain & Behavior Research Foundation awards research grants to develop improved treatments, cures, and methods of prevention for mental illness.